News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
748,869 Results
Type
Article (52406)
Company Profile (311)
Press Release (696152)
Multimedia
Podcasts (112)
Webinars (13)
Section
Business (216034)
Career Advice (3053)
Deals (37510)
Drug Delivery (119)
Drug Development (85825)
Employer Resources (189)
FDA (17113)
Job Trends (16033)
News (367394)
Policy (35737)
Tag
Academia (2856)
Accelerated approval (6)
Adcomms (27)
Allergies (92)
Alliances (54009)
ALS (96)
Alzheimer's disease (1453)
Antibody-drug conjugate (ADC) (150)
Approvals (17088)
Artificial intelligence (289)
Autoimmune disease (26)
Automation (16)
Bankruptcy (386)
Best Places to Work (12182)
BIOSECURE Act (22)
Biosimilars (117)
Biotechnology (198)
Bladder cancer (83)
Brain cancer (30)
Breast cancer (288)
Cancer (2375)
Cardiovascular disease (199)
Career advice (2556)
Career pathing (34)
CAR-T (163)
Cell therapy (457)
Cervical cancer (20)
Clinical research (69594)
Collaboration (898)
Compensation (547)
Complete response letters (29)
COVID-19 (2810)
CRISPR (47)
C-suite (256)
Cystic fibrosis (106)
Data (2247)
Decentralized trials (2)
Denatured (38)
Depression (51)
Diabetes (294)
Diagnostics (6652)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (47)
Drug discovery (127)
Drug pricing (121)
Drug shortages (31)
Duchenne muscular dystrophy (100)
Earnings (89085)
Editorial (42)
Employer branding (23)
Employer resources (163)
Events (117805)
Executive appointments (750)
FDA (18417)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (796)
Gene editing (117)
Generative AI (26)
Gene therapy (339)
GLP-1 (818)
Government (4822)
Grass and pollen (6)
Guidances (67)
Healthcare (19929)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (137)
Indications (30)
Infectious disease (2963)
Inflammatory bowel disease (151)
Inflation Reduction Act (10)
Influenza (55)
Intellectual property (101)
Interviews (561)
IPO (17058)
IRA (50)
Job creations (4277)
Job search strategy (2123)
Kidney cancer (10)
Labor market (38)
Layoffs (516)
Leadership (24)
Legal (8916)
Liver cancer (79)
Lung cancer (341)
Lymphoma (158)
Machine learning (7)
Management (64)
Manufacturing (335)
MASH (71)
Medical device (13975)
Medtech (13980)
Mergers & acquisitions (20990)
Metabolic disorders (763)
Multiple sclerosis (85)
NASH (23)
Neurodegenerative disease (105)
Neuropsychiatric disorders (34)
Neuroscience (2039)
NextGen: Class of 2025 (7052)
Non-profit (4826)
Now hiring (40)
Obesity (411)
Opinion (271)
Ovarian cancer (77)
Pain (97)
Pancreatic cancer (86)
Parkinson's disease (155)
Partnered (23)
Patents (245)
Patient recruitment (116)
Peanut (50)
People (60661)
Pharmaceutical (96)
Pharmacy benefit managers (21)
Phase I (21577)
Phase II (30567)
Phase III (22900)
Pipeline (1244)
Policy (166)
Postmarket research (2849)
Preclinical (9223)
Press Release (70)
Prostate cancer (110)
Psychedelics (37)
Radiopharmaceuticals (258)
Rare diseases (420)
Real estate (6502)
Recruiting (73)
Regulatory (24252)
Reports (48)
Research institute (2543)
Resumes & cover letters (498)
Rett syndrome (5)
RNA editing (5)
RSV (46)
Schizophrenia (80)
Series A (142)
Series B (90)
Service/supplier (12)
Sickle cell disease (57)
Special edition (18)
Spinal muscular atrophy (159)
Sponsored (32)
Startups (3945)
State (2)
Stomach cancer (16)
Supply chain (74)
Tariffs (45)
The Weekly (72)
Vaccines (778)
Venture capitalists (43)
Weight loss (287)
Women's health (37)
Worklife (19)
Date
Today (205)
Last 7 days (920)
Last 30 days (2739)
Last 365 days (34050)
2025 (11163)
2024 (36573)
2023 (41481)
2022 (52731)
2021 (57397)
2020 (56245)
2019 (49303)
2018 (37408)
2017 (34542)
2016 (34356)
2015 (40167)
2014 (34155)
2013 (29372)
2012 (31498)
2011 (32166)
2010 (30450)
Location
Africa (940)
Alabama (54)
Alaska (7)
Arizona (249)
Arkansas (14)
Asia (43023)
Australia (7078)
California (6228)
Canada (2038)
China (548)
Colorado (274)
Connecticut (284)
Delaware (152)
Europe (93849)
Florida (933)
Georgia (216)
Idaho (59)
Illinois (570)
India (28)
Indiana (324)
Iowa (11)
Japan (168)
Kansas (107)
Kentucky (27)
Louisiana (11)
Maine (68)
Maryland (930)
Massachusetts (4714)
Michigan (223)
Minnesota (405)
Mississippi (2)
Missouri (82)
Montana (28)
Nebraska (25)
Nevada (64)
New Hampshire (68)
New Jersey (1757)
New Mexico (30)
New York (1784)
North Carolina (1023)
North Dakota (9)
Northern California (2709)
Ohio (211)
Oklahoma (14)
Oregon (40)
Pennsylvania (1394)
Puerto Rico (12)
Rhode Island (33)
South America (1327)
South Carolina (24)
South Dakota (1)
Southern California (2334)
Tennessee (102)
Texas (929)
United States (23757)
Utah (186)
Virginia (155)
Washington D.C. (63)
Washington State (572)
West Virginia (3)
Wisconsin (57)
748,869 Results for "kinetix pharmaceuticals inc merged with amgen see amgen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Legal
Regeneron Loses Appeal to Block Amgen’s Eylea Biosimilar
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea.
March 17, 2025
·
2 min read
·
Tristan Manalac
Earnings
Amgen Advocates For ‘Pro-Growth Tax Policy’ Instead of Tariffs to Boost Domestic Manufacturing
Like fellow Big Pharmas Eli Lilly and Johnson & Johnson, Amgen is urging the Trump administration to consider tax policy instead of tariffs to promote domestic pharma manufacturing.
May 2, 2025
·
2 min read
·
Tristan Manalac
Earnings
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.
February 5, 2025
·
3 min read
·
Tristan Manalac
Autoimmune disease
Amgen’s Uplizna Deepens Response Against Myasthenia Gravis at 1 Year
With what analysts are calling “strong” data, Amgen plans to file a regulatory submission for Uplizna, currently approved for a rare ocular autoimmune disorder, in myasthenia gravis, in the first half of 2025.
March 13, 2025
·
1 min read
·
Tristan Manalac
Collaboration
Amgen, Ideaya Call It Quits on Cancer Combo
Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in MTAP-null advanced non-small cell lung cancer.
February 14, 2025
·
2 min read
·
Tristan Manalac
Weight Loss
‘Bulls Disappointed’ as Amgen’s MariTide Demonstrates 20% Weight Loss
With Amgen’s MariTide results at the lower end of investors’ expectation of 20% to 25% weight loss, the much-anticipated readout sent the company’s shares tumbling.
November 26, 2024
·
2 min read
·
Annalee Armstrong
Pipeline
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen
JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in the coming year.
January 15, 2025
·
4 min read
·
Tristan Manalac
Immunology and inflammation
Amgen’s Uplizna Deepens Response Through 1 Year in Myasthenia Gravis
Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be competitors in generalized myasthenia gravis.
April 10, 2025
·
2 min read
·
Tristan Manalac
Regulatory
FDA Pushes Back PDUFA Dates for Amgen and Intercept
The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic colorectal cancer and Intercept Pharmaceuticals’ Ocaliva for primary biliary cholangitis.
October 18, 2024
·
2 min read
·
Tristan Manalac
Regulatory
FDA Action Alert: Amgen, Aldeyra and Argenx
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
March 31, 2025
·
3 min read
·
Tristan Manalac
1 of 74,887
Next
